1. Pink Sheet

The Evolution Of Drug Regulation In Post-Brexit Britain

 
• By Francesca Bruce

Regulatory reliance is playing an increasingly important role in gaining marketing authorization in the UK following Brexit. Meanwhile, the country’s unique Innovative Licensing and Access Pathway is attracting growing levels of interest, not just from companies but from regulators and health technology appraisal bodies across the world.

UK Drugs
The UK's ILAP aims to marry regulatory and HTA processes to deliver quicker market access for drugs • Source: Shutterstock

The post-Brexit UK is continuing to make its way outside the EU with a view to ensuring it is an important market for attracting investment, launching innovative new medicines and conducting clinical research. The Pink Sheet takes a look at how the country is managing to develop its regulatory and market access environment in an effort to achieve those aims.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

More from Europe